AIM ImmunoTech Inc (AMEX: AIM) is -24.04% lower on its value in year-to-date trading and has touched a low of $0.13 and a high of $0.62 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AIM stock was last observed hovering at around $0.14 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $0.15, the stock is -20.63% and -25.82% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.87 million and changing 5.84% at the moment leaves the stock -49.51% off its SMA200. AIM registered -60.42% loss for a year compared to 6-month loss of -43.14%. The firm has a 50-day simple moving average (SMA 50) of $0.2048 and a 200-day simple moving average (SMA200) of $0.29935.
The stock witnessed a -30.05% gain in the last 1 month and extending the period to 3 months gives it a -38.51%, and is -16.49% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 16.24% over the week and 10.53% over the month.
AIM ImmunoTech Inc (AIM) has around 26 employees, a market worth around $10.34M and $0.19M in sales. Profit margin for the company is -12594.21%. Distance from 52-week low is 14.81% and -75.74% from its 52-week high. The company has generated returns on investments over the last 12 months (-686.04%).
with sales reaching $100k over the same period.The EPS is expected to grow by 50.00% this year, but quarterly earnings will post -0.99% year-over-year. Quarterly sales are estimated to grow 53.85% in year-over-year returns.
AIM ImmunoTech Inc (AIM) Top Institutional Holders
33.0 institutions hold shares in AIM ImmunoTech Inc (AIM), with institutional investors hold 15.39% of the company’s shares. The shares outstanding are 68.75M, and float is at 60.53M with Short Float at 1.04%. Institutions hold 14.07% of the Float.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 4.08 million shares valued at $1.52 million. The investor’s holdings represent 8.2454% of the AIM Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 1.99 million shares valued at $$0.74 million to account for 4.021 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 0.7 million shares representing 1.4118% and valued at over $0.26 million, while GEODE CAPITAL MANAGEMENT, LLC holds 0.8108 of the shares totaling 0.4 million with a market value of $0.15 million.
AIM ImmunoTech Inc (AIM) Insider Activity
The most recent transaction is an insider purchase by Equels Thomas K,the company’sCEO & President. SEC filings show that Equels Thomas K bought 20,000 shares of the company’s common stock on Nov 21 ’24 at a price of $0.21 per share for a total of $4240.0. Following the purchase, the insider now owns 1.66 million shares.
AIM ImmunoTech Inc disclosed in a document filed with the SEC on Dec 19 ’24 that MITCHELL WILLIAM M (Director) sold a total of 4,580 shares of the company’s common stock. The trade occurred on Dec 19 ’24 and was made at $0.19 per share for $884.0. Following the transaction, the insider now directly holds 0.12 million shares of the AIM stock.
Still, SEC filings show that on Dec 18 ’24, Equels Thomas K (CEO & President) acquired 22,727 shares at an average price of $0.21 for $4682.0. The insider now directly holds 1,680,695 shares of AIM ImmunoTech Inc (AIM).
